Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:CBST
Raised
Post IPO Valuation

General Information

Websitecubist.com
Twitter@cubistbiopharma
CategoryBioTech
Phone781-860-8660
Employees
Founded1992

Offices

Lexington, USA
65 Hayden Avenue
Lexington, MA, 02421
USA

People

CEO
Chairman of the Board
CFO
COO
Board of Directors
Director, Talent Acquisition
Director
Senior Vice President and Chief Financial Officer
Senior Director, Talent Management

Acquisitions

Total$1.79B
Optimer Pharmaceuticals, 7/2013 $535M
Trius Therapeutics, 7/2013 $707M
Adolor, 12/2011 $453M
Calixa Therapeutics, 12/2009 $92.5M

Tags

Cubist Pharmaceuticals

Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam’s RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.

Recent Milestones

Videos

Screenshots

Cubist Pharmaceuticals screenshot
Above: Cubist Pharmaceuticals Screenshot -- #1
Uploaded: 12/15/09

Stock Price

Sources

  1. Cubist Pharmaceuticals to buy Trius Therapeutics, Optimer Pharmaceuticals for up to $1.6 billion (firstwordpharma.com) [edit]
  2. Cubist Pharmaceuticals to Acquire Trius Therapeutics (businesswire.com) [edit]
  3. Cubist completes Adolor acquisition at about $453M (masshightech.com) [edit]
  4. Cubist buying Calixa Therapeutics for up to $402.5M (masshightech.com) [edit]
  5. Cubist expanding in Lexington, adding new jobs (masshightech.com) [edit]
    Mass High Tech (masshightech.com) [edit]
    Cubist names Bate as non-exec board chairman (masshightech.com) [edit]
    Cubist collaboration on diarrhea drug could net $47M (masshightech.com) [edit]
Edit This Page
Last Edited 3/26/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy